Tags

Type your tag names separated by a space and hit enter

In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals.

Abstract

Bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis (TB) in humans and animals. It is most commonly administered parenterally, but oral delivery is highly advantageous for the immunisation of cattle and wildlife hosts of TB in particular. Since BCG is susceptible to inactivation in the gut, vaccine formulations were prepared from suspensions of Eudragit L100 copolymer powder and BCG in phosphate-buffered saline (PBS), containing Tween® 80, with and without the addition of mannitol or trehalose. Samples were frozen at -20 °C, freeze-dried and the lyophilised powders were compressed to produce BCG-Eudragit matrices. Production of the dried powders resulted in a reduction in BCG viability. Substantial losses in viability occurred at the initial formulation stage and at the stage of powder compaction. Data indicated that the Eudragit matrix protected BCG against simulated gastric fluid (SGF). The matrices remained intact in SGF and dissolved completely in simulated intestinal fluid (SIF) within three hours. The inclusion of mannitol or trehalose in the matrix provided additional protection to BCG during freeze-drying. Control needs to be exercised over BCG aggregation, freeze-drying and powder compaction conditions to minimise physical damage of the bacterial cell wall and maximise the viability of oral BCG vaccines prepared by dry powder compaction.

Links

Authors+Show Affiliations

,

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK. I.Saleem@ljmu.ac.uk.

,

Pharmacy Australia Centre of Excellence, University of Queensland, School of Pharmacy, 20 Cornwall Street, Woolloongaba, QLD 4102, Australia. allancoombes1@gmail.com.

Department of Bacteriology, Animal and Plant Health Agency, Woodham Lane, New Haw, Addlestone, Surrey KT15 3NB, UK. mark.chambers@apha.gov.uk. School of Veterinary Medicine, University of Surrey, VSM Building, Daphne Jackson Rd, Guildford GU2 7AL, UK. mark.chambers@apha.gov.uk.

Source

Pharmaceutics 11:6 2019 Jun 10 pg

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31185612

Citation

Saleem, Imran, et al. "In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals." Pharmaceutics, vol. 11, no. 6, 2019.
Saleem I, Coombes AGA, Chambers MA. In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals. Pharmaceutics. 2019;11(6).
Saleem, I., Coombes, A. G. A., & Chambers, M. A. (2019). In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals. Pharmaceutics, 11(6), doi:10.3390/pharmaceutics11060270.
Saleem I, Coombes AGA, Chambers MA. In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals. Pharmaceutics. 2019 Jun 10;11(6) PubMed PMID: 31185612.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In Vitro Evaluation of Eudragit Matrices for Oral Delivery of BCG Vaccine to Animals. AU - Saleem,Imran, AU - Coombes,Allan G A, AU - Chambers,Mark A, Y1 - 2019/06/10/ PY - 2019/04/04/received PY - 2019/06/03/revised PY - 2019/06/04/accepted PY - 2019/6/13/entrez KW - BCG KW - Eudragit KW - in vitro viability KW - oral vaccine KW - tuberculosis JF - Pharmaceutics JO - Pharmaceutics VL - 11 IS - 6 N2 - Bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis (TB) in humans and animals. It is most commonly administered parenterally, but oral delivery is highly advantageous for the immunisation of cattle and wildlife hosts of TB in particular. Since BCG is susceptible to inactivation in the gut, vaccine formulations were prepared from suspensions of Eudragit L100 copolymer powder and BCG in phosphate-buffered saline (PBS), containing Tween® 80, with and without the addition of mannitol or trehalose. Samples were frozen at -20 °C, freeze-dried and the lyophilised powders were compressed to produce BCG-Eudragit matrices. Production of the dried powders resulted in a reduction in BCG viability. Substantial losses in viability occurred at the initial formulation stage and at the stage of powder compaction. Data indicated that the Eudragit matrix protected BCG against simulated gastric fluid (SGF). The matrices remained intact in SGF and dissolved completely in simulated intestinal fluid (SIF) within three hours. The inclusion of mannitol or trehalose in the matrix provided additional protection to BCG during freeze-drying. Control needs to be exercised over BCG aggregation, freeze-drying and powder compaction conditions to minimise physical damage of the bacterial cell wall and maximise the viability of oral BCG vaccines prepared by dry powder compaction. SN - 1999-4923 UR - https://www.unboundmedicine.com/medline/citation/31185612/In_Vitro_Evaluation_of_Eudragit_Matrices_for_Oral_Delivery_of_BCG_Vaccine_to_Animals DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for WindowsUnbound PubMed app for MAC OSX Yosemite Macbook Air pro